

Title: The Role of ACT Score in Mepolizumab Discontinuation

*Neha Solanki, MD¹, Brittany Beck², Monica Labadia², Kevin Smith², Laura Peterson², Stephanie King, MSN, RN¹, Sarah Micklewright, PA-C¹, Emily Pennington, MD¹, Sobia Farooq, MD¹, Peng Zhang, MD¹, Mark Aronica, MD¹, Joe Zein, MD, PhD^{1,2}, Sumita Khatri, MD, MS³, Suzy Comhair, PhD², Serpil Erzurum, MD^{1,2}
¹Respiratory Institute, Cleveland Clinic, ²Lerner Research Institute, Cleveland Clinic, ³National Heart, Lung, and Blood Institute

Abstract:

Background: Mepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external validity and diverse population from the US are lacking. There is little knowledge of the characteristics of people that discontinue mepolizumab in clinical care.

Objective: To investigate the real-world efficacy and time to clinical discontinuation of mepolizumab, we evaluated individuals with asthma started on mepolizumab at the Cleveland Clinic. We hypothesized that there are characteristics that distinguish which patients would remain on mepolizumab and which patients would discontinue the medication.

Methods: Between 2016 and 2022, patients who started on mepolizumab consented to be assessed over 18 months. At baseline, a questionnaire including demographic and medical history was collected. Laboratory findings such as ACT score, F_ENO (Fractional Excretion of Nitric Oxide), and spirometry were recorded. At the conclusion of the observation period, the participants were divided into two categories: Group A and Group B.

Results: Group B [N=28] discontinued mepolizumab ($P < 0.05$) at an average of 5.8 months (SD 4.2 months). Group A [N=129] stayed on the therapy for at least 1 year. A participant with an ACT score less than 13 has an odds ratio of 6.64 (95% CI, 2.1 – 26.0) of discontinuing mepolizumab therapy. For a male, the odds of discontinuing mepolizumab therapy is 3.39 (95% CI, 1.1 – 11.2).

Conclusion: In this real-world study, we find that high eosinophil count may not be adequate in screening which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.

Abstract Word Count: 263

Word Count: 2862

Keywords: Asthma, asthma control, mepolizumab

Abbreviations:

ACT = asthma control test; AUC = area under curve; BMI = body mass index; CAD = coronary artery disease; CBC = complete blood count; CHF = congestive heart failure; DBP = diastolic blood pressure; Federal Drug Administration = FDA; F_ENO = fractional excretion of nitric oxide; FEV₁ = forced expiratory volume in one second; GERD = gastroesophageal reflux disease; GINA = Global Initiative for Asthma; GSK = GlaxoSmithKline; ICS = inhaled corticosteroids; IQR = interquartile range; IRB = Institutional Review Board; LABA = Long-acting beta agonist; μ L = microliters; ROC = receiver operating curve; SBP = systolic blood pressure; WBC = white blood cell.

*Dr. Khatri contributed to the article as an employee of the Cleveland Clinic. The views expressed are her own and not necessarily represent the views of the National Institutes of Health or the United States Government.

12
13
14 **Introduction:**

15 People with severe and uncontrolled asthma experience the highest impact on quality of life and
16 accompanying morbidity from asthma. Severe asthma, which is uncontrolled asthma despite
17 adherence to high dose inhaled corticosteroids (ICS) and long-acting beta agonist treatment (LABA),
18 is present in 5%-10% of people with asthma (1, 2). Caregivers have new and exciting management
19 options for steroid-sparing medications including treatment with monoclonal antibodies also known as
20 biologic agents that target immunoglobulin E (IgE), interleukin 5, interleukin-5 receptor, or interleukin-
21 4 receptor (3). The introduction of biologic therapy to the treatment of severe asthma represents an
22 opportunity to carry out phenotype-specific intervention, reinforcing the need for precision in diagnosis
23 (1). Though the Global Initiative for Asthma (GINA) does include a decision tree for how to choose a
24 biologic agent for an individual with severe asthma, many individuals remain uncontrolled and can
25 remain on a biologic agent for longer than necessary (2). People with severe and uncontrolled
26 asthma experience the highest impact on quality of life and accompanying morbidity from asthma.
27 Additionally, according to GINA, the cost of treating individuals with severe asthma is higher when
28 compared to the cost of treating the general population for asthma (2, 4), which further underscores
29 the possible benefits for precision medicine in asthma control and healthcare costs.

30 GlaxoSmithKline's (GSK) mepolizumab, a humanized, interleukin-5 antagonist monoclonal antibody,
31 received approval from the US FDA (Federal Drug Administration) in 2015 for add-on treatment in
32 adults with severe eosinophilic asthma (5). The clinical trials that evaluated mepolizumab in patients
33 with asthma included three double-blind, randomized, placebo-controlled studies, including DREAM
34 (Dose Ranging Efficacy And safety with Mepolizumab in severe asthma; NCT01000506), the Phase
35 III MENSA (MEpolizumab as adjuNctive therapy in patients with Severe Asthma; NCT01691521) trial,
36 and SIRIUS (Steroid Reductlon with mepolizUmab Study; NCT01691508) (5). The DREAM trial
37 showed that a baseline blood eosinophil count and increased exacerbation frequency in the previous

58 year were associated with good response to mepolizumab. The confirmatory trials required patients
59 to have a blood eosinophil level greater than or equal to 150 cells/ μ L at screening or blood eosinophil
60 levels greater than or equal to 300 cells/ μ L within one year of enrollment (6). SIRIUS, a 24-week
61 clinical trial, demonstrated that mepolizumab has a significant glucocorticoid-sparing effect compared
62 with placebo (6). In patients with baseline eosinophil counts greater than or equal to 150 cells/ μ L,
63 the DREAM, MENSA, and MUSCA (Mepolizumab adjunctive therapy in subjects with Severe
64 eosinophilic Asthma; NCT02281318) trials demonstrated that mepolizumab treatment reduces
65 exacerbations, increases forced expiratory volume in one second (FEV₁) and improves asthma
66 control and quality of life (5). While clinical trials are pivotal for FDA-approval of new therapies, real
67 world applications of medicines can often reveal different outcomes than in prospective blinded trials
68 (7).

69 To assess real-world effects of mepolizumab, Glaxo Smith Kline (GSK) funded REALITI-A (REAL
70 world effectiveness of mepolizumab in patient care – Asthma), a large prospective study with 368
71 participants. REALITI-A demonstrated a meaningful reduction in daily maintenance oral corticosteroid
72 dose for people with asthma and a decrease in the rate of exacerbations. However, there was not a
73 difference shown for FEV₁ (forced expiratory value in 1 second) % (5). Observational real-world
74 cohorts from Europe also showed that mepolizumab reduces prednisone dependence and improves
75 asthma control (8-10). Israeli and Australian studies demonstrate an additional FEV₁% improvement
76 (11, 12). The results from this real-world study suggest that more data are needed regarding the
77 effects of mepolizumab on FEV₁% and the time to mepolizumab's clinical failure for a person with
78 very severe asthma.

79 To further investigate the real-world efficacy of mepolizumab, time to discontinuation of mepolizumab
80 and identification of clinical traits of those who remain on mepolizumab, we evaluated people with
81 asthma treated with mepolizumab at the Asthma Center of Cleveland Clinic over 6 years. We
82 hypothesized that there may be baseline characteristics that distinguish which patients will respond to

mepolizumab and the characteristics of the type of response, including better asthma control, lower corticosteroid dose, and better lung functions.

Methods:

Baseline Characteristics

Cleveland Clinic's biologic registry includes individuals on omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab. An asthma specialist assessed eligible participants in the registry and prescribed mepolizumab based on standard U.S guidelines at the time of study. These guidelines included an absolute blood count eosinophil ≥ 150 cells/ μL or corticosteroid dependence and clinical evidence of uncontrolled asthma as demonstrated by two or more asthma exacerbations requiring prednisone, one or more hospitalizations or emergency medical visits or poor symptom control while being on an inhaled corticosteroid and a long-acting beta-agonist. Between 2016 and 2022, we consented 199 people who were prescribed mepolizumab by their provider. The Institutional Review Board (IRB # 8351) at Cleveland Clinic approved the study protocol and procedure.

Longitudinal Assessment

The study team assessed each participant at baseline visit prior to first dose of mepolizumab, and then at 3 months, 6 months, 12 months, and 18 months (Figure 1). At the baseline visit, our team collected a questionnaire which included demographic information, asthma history, medical history, review of systems, asthma medications, and healthcare utilization from each participant (Figure 1). We also recorded peak flow, ACT score, $F_{\text{E}}\text{NO}$, spirometry and CBC, and we conducted similar assessments of the participants in subsequent visits.

Outcomes

17 The outcome of this retrospective study was discontinuation of mepolizumab therapy based on lack of
18 clinical response, which was determined by the asthma specialist and informed by the patient's
19 perspective and the provider's medical reasoning. After 18 months of serial assessments, participants
20 who started mepolizumab were divided into two categories: Group A and Group B. We defined Group
21 A participants received mepolizumab for at least six months or received mepolizumab for 18 months
22 without a change in therapy. Group B participants stopped the therapy within 6 months or had a
23 clinical need to switch to a different biologic therapy within 18 months. Chart review excluded
24 participants who stopped mepolizumab therapy due to other reasons .

25 *Statistical analysis*

26 We performed all analyses with R, version 4.1.2 (R Project for Statistical Computing, Vienna, Austria),
27 and we reported results as mean with standard deviation or median with interquartile range
28 depending on whether the value was parametric or non-parametric. For the descriptive analysis, we
29 used student's t-test or Kruskal-Wallis test to compare participants on mepolizumab to those on other
30 biologics and to compare mepolizumab responders and non-responders. Categorical variables were
31 analyzed using chi-squared tests. Comorbidities that have 10% or higher missing data were
32 excluded. Several columns that had over 10% of "missing" values were excluded.

33
34 We used a Kaplan-Meier curve to compare time on the drug for mepolizumab responders and non-
35 responders. Each responders' time was censored after 18 months. When data were censored, the
36 total time on mepolizumab for a subject cannot be accurately determined past a certain date. Log
37 rank was used to calculate P for the Kaplan-Meier curve. A receiver operative curve (ROC) with C-
38 index was used to determine optimal cutoff for discrete variables with $P < 0.05$ between responders
39 and non-responders. For the inferential analysis, binomial logistic regression was utilized to obtain
40 odds ratio with confidence intervals. In this analysis, less than 4% of data were missing and were
41 deemed missing completely at random.

12

13 **Results:**

Of the participants who started on mepolizumab ($n = 199$), the top reason for exclusion is lack of recorded follow-up visits ($n = 27$). Participants ($n = 15$) are excluded for medication side effects, loss to follow up, or change in medication indication (Figure 2a). 157 (70.4%) of the participants who started on mepolizumab at their baseline visits are included in this analysis (Figure 2b). The group that started mepolizumab and the group that started other biologic agents have similar baseline demographic characteristics and medical comorbidities (Table 1) except for a higher prevalence nasal polyps ($n = 69$ versus [vs] $n = 16$, $P < 0.05$) and sinusitis ($n = 112$ vs $n = 30$, $P < 0.05$) in participants placed on mepolizumab. Participants starting mepolizumab are also more prednisone dependent ($n = 98$ vs $n = 24$, $P < 0.001$). There are no differences in asthma control score, eosinophil counts, and daily oral prednisone use between the two groups (Table 1).

14 For the participants placed on mepolizumab ($n = 157$), there is gradual attrition over visits 3, 6, 12, 18
15 months (Figure 3). Despite attrition, median ACT scores improve over sequential visits on
16 mepolizumab ($P < 0.05$) (Figure 4-A). FEV₁ improves rapidly in most individuals between the baseline
17 visit and 3 months, however it is not sustained ($P < 0.05$) (Figure 4-B). There is a striking decline in
18 prednisone use between visit 1 and subsequent visits ($P < 0.05$) (Figure 4-C).

19

20 Of the 157 individuals on mepolizumab, 129 are classified as Group A and 28 as Group B (Table 2).
21 Group B participants are on mepolizumab therapy ($P < 0.05$) for an average of 5.8 months (standard
22 deviation [SD] 4.2 months) (Figure 5). Participants in Group A demonstrated a higher ACT score at
23 each subsequent visit (Figure 6A); whereas participants in Group B did not demonstrate a change in
24 ACT score through subsequent visits (Figure 6B). Group B participants have lower median baseline

55 ACT of 9 (interquartile range [IQR], 4) compared to 13 (IQR, 9) for responders ($P < 0.05$) (See Figure
56 7). There are no other differences between the baseline characteristics of the two groups (Table 2).
57 Sub-analysis of people with nasal polyps demonstrates that there is no difference in the people who
58 discontinue mepolizumab and those who stay on the medication (Table 3).

59 Based on the observed difference in ACT of the groups, the area under the curve (AUC) of the
60 receiver operative curve analysis was 0.68 for an ACT cutoff score of 13 (Figure 8). Binomial logistic
61 regression controlled for age, BMI (Body Mass Index), $F_{E}NO$, and eosinophils show that for a
62 participant who has an ACT score less than 13, the odds ratio of being in Group B is 6.64 (95% CI,
63 2.1 – 26.0) (Figure 9). Men have an odds ratio of 3.39 (95% CI, 1.1 – 11.2) for being in Group B
64 (Figure 9)

56 Discussion:

57 Utilizing this real-world cohort of people with severe asthma, we find that most people on
58 mepolizumab demonstrate clinical improvement shown by a decrease in ACT score by 18 months, a
59 decrease in prednisone use as soon as 3 months, and an initial increase in $FEV_1\%$ by 3 months. Our
60 findings also corroborate the REALITI-A trial and other real-world studies, but unlike others, this study
61 is sponsored in part by NIH. When compared to the cohorts on other biologic therapy, the
62 mepolizumab cohort comprises this registry's longest and most complete longitudinal data. This
63 study, which is the largest US real-world mepolizumab to date, shows that despite having eosinophils
64 ≥ 150 cells/ μ L and history of recurrent asthma exacerbations, male sex or a person with severe
65 asthma who has an ACT score < 13 is more likely to discontinue mepolizumab therapy. Our findings
66 also show that if mepolizumab is discontinued, the discontinuation will occur within 6 months of
67 starting the drug; those that stay on mepolizumab and demonstrate an improvement in ACT score are
68 on mepolizumab for at least an average of 1 year. The results suggest that poorly controlled asthma
69 at baseline and men with severe asthma may have a different biologic endotype less responsive to

30 IL-5 therapy. A sub-analysis of Group B including those individuals initially excluded for side effects
31 demonstrates that sex remains a critical variable for discontinuing mepolizumab at 6 months.
32 Additionally, those with a lower baseline ACT score still are more likely to discontinue mepolizumab at
33 6 months. These findings in the intention-to-treat sub-analysis bolster the initial findings (Table 4).

34
35 Participants of Group B may have a complex neutrophilic or pauci-granulocytic mechanism for their
36 asthma because Type 2 (T2) inflammation-mediated asthma responds well to mepolizumab (13).
37 Another possibility is that their asthma may be not controlled well at baseline. Predictive biomarkers
38 for response to mepolizumab treatments so far include blood eosinophil counts as the strongest
39 predictor for the reduction in exacerbation rates with mepolizumab compared to placebo (14).
40 However, in our study, eosinophil counts are similar among responders and non-responders. The
41 Australian Mepolizumab Registry did find that higher blood eosinophil levels and a better baseline
42 Asthma Control Questionnaire (ACQ-5) predicted a superior clinical response to mepolizumab (11).

43
44 Regarding sex as a risk factor, 31% of the participants in our study on mepolizumab are male. While
45 most of the participants in our study are female, males were found to have an odds ratio of 3.39 of
46 failing mepolizumab therapy. The Australian Mepolizumab Registry also found that males were more
47 likely to fail mepolizumab therapy (11). Sex hormones play a role in asthma severity, and androgens
48 such as testosterone may reduce asthma incidence and symptoms (15). Therefore, the finding that
49 males have higher odds of failing mepolizumab therapy is unexpected and may suggest underlying
50 sex-based mechanism for this subset.

51
52 For our study, the median FEV₁% improves by 3 months on the therapy. Most people also have a
53 decrease in prednisone use by the third month. Therefore, we expected FEV₁% to stay consistent or

04 continue improving after visit 3, but we do not find any remarkable differences past the third month on
05 mepolizumab. Therefore, while there may be an initial improvement in FEV₁% by the third month, the
06 effect is not long-lasting. Pre-bronchodilator FEV₁% is lower at baseline for participants (though $P >$
07 0.05) who are clinical non-responders compared to clinical responders. If the study had higher power,
08 it is possible that this difference would become more pronounced. REALITI-A does not show a
09 difference shown for FEV₁% (5), but Israeli and Australian studies demonstrate an FEV₁%
10 improvement (11, 12). Obesity, which causes changes to normal lung physiology, innate immune
11 function, and changes in the gut microbiome, is a major risk factor and disease modifier in asthma for
12 adults (16). The BMI values of people on mepolizumab trend higher than the BMI values of people
13 placed on other biologics (32.1 [9.7] vs 30 [12.1] ($P = 0.171$), and the BMI values of Group B trend
14 higher than the BMI values of Group A (32.5 [7.8] vs 31 [12] ($P = 0.513$). Obesity causes mechanical
15 changes such as lung compression and reduction in lung volume (16). As BMI increases, there is a
16 higher risk for airway hyperreactivity (17). Additionally, the Western dietary pattern, which promotes
17 obesity, might also affect the development of asthma via changes in gut microbiome (16).

18 While this study has many strengths such as strong external validity because it is a real-world study
19 and has a diverse demographic population, it has three limitations. In a real-world study, there are no
20 controls and no randomization. The first limitation in our study is that participants who started on
21 mepolizumab compared to those that started on other biologic agents have higher a prevalence of
22 chronic rhinosinusitis with nasal polyposis (CRSwNP). After the randomized controlled trial,
23 SYNAPSE, mepolizumab was approved for nasal polyps in the setting of severe chronic rhinosinusitis
24 (18). However, those with greater type 2 inflammation often have concomitant CRSwNP, so it is not
25 surprising that clinicians chose mepolizumab for those with this comorbidity (19). Since the people
26 started on mepolizumab have a higher incidence of CRSwNP in this study, these people likely have
27 greater Th2 inflammation which suggests that the population on mepolizumab, regardless of when
28 they discontinue the medication, are going to have more severe asthma at baseline than the people

29 placed on other biologics, which is supported by the higher use of prednisone (62% vs 36%, $P <$
30 0.001). Our sub-analysis of the cohort with CRSwNP demonstrated that there was no difference in the
31 people that stayed on mepolizumab and those that discontinued it early (Table 3).

32
33 A second limitation is that the individuals in Group A have either milder asthma or better controlled at
34 baseline as they have a higher baseline ACT score and a better baseline FEV₁ (72% vs 62%
35 predicted, $P = 0.07$). It is difficult to ascertain just based on this observational review whether the
36 participants of Group B have asthma that is severe and uncontrolled or just uncontrolled at baseline.
37 Finally, since this was a real-world study, there is also attrition between the baseline visit and visit 18,
38 which reduces the power of our study. If an individual left the study to receive their asthma
39 management at another facility, their information was not recorded. This further reduces the power of
40 our study. It is remarkable that given the limitations, we still were able to corroborate the findings of
41 DREAM, MENSA, MUSCA, SIRIUS, and REALITI-A, and we were also able to find a strong
42 relationship between ACT score and mepolizumab response.

43 In conclusion, upto 17% of patients discontinue therapy within 6 months, with male sex and low ACT
44 score increasing risk of early discontinuation.. One mechanism for low ACT scores in the people that
45 discontinue mepolizumab early could be related to altered gut microbiome in the setting of obesity
46 with an altered immune response favoring low Th2 pathways that would be less responsive to
47 biologics targeting Th2 high pathways, despite having a high baseline eosinophil count. Further
48 studies are needed to determine which, if any, biologics might perform better in those people who
49 suffer with severe asthma and poor control.

- 52 1 Lopez-Tiro J, Contreras-Contreras A, Rodriguez-Arellano ME, Costa-Urrutia P. Economic burden of severe asthma
53 treatment: A real-life study. *World Allergy Organ J.* 2022;15(7):100662.
- 54 2. Venkatesan P. 2023 GINA report for asthma. *Lancet Respir Med.* 2023.
- 55 3. Reibman J, Tan L, Ambrose C, Chung Y, Desai P, Llanos JP, et al. Clinical and economic burden of severe asthma
56 among US patients treated with biologic therapies. *Ann Allergy Asthma Immunol.* 2021;127(3):318-25 e2.
- 57 4. Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of Severe Asthma
58 Worldwide: Data From the International Severe Asthma Registry. *Chest.* 2020;157(4):790-804.
- 59 5. Pavord ID, Bel EH, Bourdin A, Chan R, Han JK, Keene ON, et al. From DREAM to REALITI-A and beyond:
60 Mepolizumab for the treatment of eosinophil-driven diseases. *Allergy.* 2022;77(3):778-97.
- 61 6. Fala L. Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance
62 Treatment of Patients with Severe Asthma. *Am Health Drug Benefits.* 2016;9(Spec Feature):106-10.
- 63 7. Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: The changing
64 landscape of the regulatory approval process. *Pharmacoepidemiol Drug Saf.* 2020;29(10):1201-12.
- 65 8. Kavanagh JE, d'Ancona G, Elstad M, Green L, Fernandes M, Thomson L, et al. Real-World Effectiveness and the
66 Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. *Chest.* 2020;158(2):491-500.
- 67 9. van Toor JJ, van der Mark SC, Kappen JH, In 't Veen J, Braunstahl GJ. Mepolizumab add-on therapy in a real world
68 cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. *J Asthma.* 2021;58(5):651-8.
- 69 10. Kroes JA, Alfonso-Cristancho R, Bansal AT, Berret E, Bieksiene K, Bourdin A, et al. Evaluation of real-world
70 mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis. *ERJ*
71 *Open Res.* 2023;9(2).
- 72 11. Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, et al. Mepolizumab effectiveness and
73 identification of super-responders in severe asthma. *Eur Respir J.* 2020;55(5).
- 74 12. Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D, Kramer MR. Efficacy and safety of
75 mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. *J Asthma.* 2021;58(1):79-84.
- 76 13. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. *Am J Respir Crit Care Med.*
77 2019;199(4):433-45.
- 78 14. Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, et al. Biomarkers for severe eosinophilic asthma.
79 *J Allergy Clin Immunol.* 2017;140(6):1509-18.
- 80 15. Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. *Eur Respir Rev.* 2021;30(162).
- 81 16. Peters U, Dixon AE, Forno E. Obesity and asthma. *J Allergy Clin Immunol.* 2018;141(4):1169-79.
- 82 17. Litonjua AA, Sparrow D, Celedon JC, DeMolles D, Weiss ST. Association of body mass index with the development
83 of methacholine airway hyperresponsiveness in men: the Normative Aging Study. *Thorax.* 2002;57(7):581-5.
- 84 18. Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic
85 rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir*
86 *Med.* 2021;9(10):1141-53.
- 87 19. Pelaia C, Pelaia G, Maglio A, Tinello C, Gallelli L, Lombardo N, et al. Pathobiology of Type 2 Inflammation in
88 Asthma and Nasal Polyposis. *J Clin Med.* 2023;12(10).

39